Intellia Phase 3 HAELO data show 87% HAE attack reduction

Intellia Therapeutics has presented full results from the global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), reporting an 87% reduction in mean monthly attacks versus placebo across a six-month efficacy evaluation window. The data were delivered in a late-breaking oral session at the European Academy of Allergy and Clinical Immunology Annual Congress 2026 in Istanbul and were simultaneously published in the New England Journal of Medicine.

The primary endpoint had been disclosed previously, but Saturday's presentation added a full picture of the key secondary endpoints. Among lonvo-z-treated patients, 62% were entirely attack-free and required no additional therapy for the six-month period, compared with 11% in the placebo arm. The monthly rate of attacks requiring on-demand treatment fell by 89% in the treated group, and the rate of moderate or severe attacks fell by 91%. Quality-of-life scores, measured using the validated Angioedema Quality of Life instrument, improved by a mean of 17 points in the lonvo-z arm versus just 6.5 points with placebo, well above the 6-point threshold considered clinically meaningful.

Safety and mechanism

The safety profile was characterised as favourable. Treatment-emergent adverse events reported more frequently in the lonvo-z group than in placebo included infusion-related reaction, headache, fatigue, back pain and upper respiratory tract infection. All were graded as mild or moderate, and no serious adverse events were recorded in the treated arm during the primary observation period. Plasma kallikrein protein levels dropped substantially by day 15, stabilised by week 5 and held steady through the February 2026 data cutoff, consistent with the intended permanent inactivation of the KLKB1 gene via CRISPR/Cas9 editing.

"These are the first Phase 3 results to deliver on the much-heralded promise of in vivo CRISPR gene editing," said John Leonard, Intellia's president and chief executive. The company says all patients in the lonvo-z arm remained free of long-term prophylaxis therapy as of the data cutoff, regardless of age or prior prophylaxis history.

Regulatory path and competitive context

A rolling biologics licence application was submitted to the US Food and Drug Administration starting in April 2026, and Intellia continues to target a US approval and commercial launch in the first half of 2027. Lonvo-z already holds Orphan Drug and RMAT designations from the FDA, an Innovation Passport from the MHRA and PRIME designation from the European Medicines Agency, regulatory markers that should streamline review in all three major jurisdictions.

The HAE treatment landscape has matured considerably over the past decade. Approved long-term prophylaxis options include subcutaneous biologics such as lanadelumab and the oral plasma kallikrein inhibitor berotralstat, as well as the RNA interference therapy garadacimab. These therapies require ongoing dosing, sometimes as frequently as twice weekly, and breakthrough attacks remain a documented problem for a subset of patients. A single-dose curative approach, if it sustains the effect seen in HAELO beyond the 28-week evaluation window, would represent a significant commercial and clinical differentiator. Longer-term durability data will be the central question for regulators, clinicians and payers assessing the case for lonvo-z against well-established chronic therapies. Intellia has not yet disclosed pricing or market access strategy, and healthcare technology assessment bodies in the UK and Europe are likely to request extended follow-up before endorsing the treatment across broad patient populations.

The NEJM publication adds independent peer-reviewed validation to the dataset, a step that typically accelerates engagement with regulatory agencies and specialist prescribers ahead of a launch.